Alector is a biotechnology company whose mission is to develop therapies that empower the immune system to cure neurodegeneration. There are currently few methods to prevent, cure, or meaningfully alter the inexorable course of neurodegenerative disease. Alector is mining the human genome to identify mutations in immune system genes that increase the risk for these disorders. The company aims to pioneer new drugs that counteract the damage these mutations cause, and ultimately find a cure.